Skip to main content
Premium Trial:

Request an Annual Quote

C2i Genomics, NovogeneAIT Genomics Partner to Launch Cancer Detection Platform in Southeast Asia

NEW YORK — C2i Genomics said on Thursday that it has signed an agreement with Singapore-based genomic services provider NovogeneAIT Genomics to launch its C2-Intelligence Platform for minimal residual disease detection in Southeast Asia.

The C2-Intelligence Platform uses artificial intelligence pattern recognition and whole-genome analysis to detect minimal residual disease in blood samples from cancer patients. According to C2i, the platform includes whole-genome tumor profiling for increased diagnostic yield and tumor-informed blood-based MRD testing for cancer burden monitoring and personalized treatment management.

Under the terms of the deal, NovogeneAIT will act as a reference lab for the platform, deploying it in its sequencing labs in Southeast Asia. The firm has also been given a nonexclusive license to distribute and market C2i's pharmaceutical and diagnostic services in the region, which include cancer patient assessment for clinical trial enrollment.

Financial and other terms were not disclosed.

Earlier this year, C2i — a New York City-based venture between the New York Genome Center and Weill Cornell Medicine researchers — raised $100 million in private financing. NovogeneAIT is a joint venture between Chinese sequencing firm Novogene and AIT Biotech, a molecular diagnostics and genomic products developer.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.